In addition, as part of Spectrum’s strategy to focus on oncology and urology, Spectrum has a portfolio of neurology drug candidates that are available for out-licensing. A list and description of these opportunities can be found below.
For more information regarding these compounds and all our various out-licensing options, please contact Russell Skibsted at: rskibsted@spectrumpharm.com.
